India moves closer to dengue vaccine as final trials underway

Dengue vaccine trials are currently underway in India, where the mosquito-borne disease is a significant public health concern. The ongoing trials of Sanofi Pasteur's tetravalent dengue vaccine, which combines four strains of the virus, aim to provide a much-needed tool for preventing this fast-spreading disease.

Dengue fever, characterized by high fevers, severe headaches, muscle and joint pains, and rashes, is endemic in many parts of India. The country has experienced a surge in cases recently, with over 150,000 reported infections in 2016. With no approved vaccine currently available, the need for an effective dengue vaccine is urgent.

The trials in India are part of larger studies that aim to validate Sanofi Pasteur's tetravalent dengue vaccine, known as Dengvaxia®, as a safe and effective tool against dengue fever. The vaccine has already undergone successful phase III clinical trials in Puerto Rico, the Dominican Republic, and several countries in Asia.

The results of the Indian trials will be crucial in determining whether Dengvaxia® can be used to protect populations at risk for this potentially deadly disease. Sanofi Pasteur officials are hopeful that, if approved, the vaccine could significantly reduce the burden of dengue fever in India and other affected regions.

In addition to the ongoing trials, Sanofi Pasteur is also working on additional vaccines targeting different strains of the virus and conducting research on improving current methods for diagnosing and treating dengue infections. The company's dedication to developing effective tools to combat this global health threat is a vital step towards protecting communities worldwide from the devastating impact of dengue fever.

As the global outbreak of dengue continues, it is essential that we explore all avenues of research to find a solution to this growing public health concern. With trials underway in India and elsewhere, there is hope that we can develop an effective vaccine to protect vulnerable populations against this dangerous disease.

Edward Lance Arellano Lorilla

CEO / Co-Founder

Enjoy the little things in life. For one day, you may look back and realize they were the big things. Many of life's failures are people who did not realize how close they were to success when they gave up.